To Preserve Patient Access To Xphozah (Tenapanor), Ardelyx Has Chosen Not To Apply To Include Xphozah In Centers For Medicare & Medicaid Services End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment
Portfolio Pulse from Benzinga Newsdesk
Ardelyx has decided not to apply for the inclusion of its drug Xphozah (Tenapanor) in the CMS End-Stage Renal Disease Prospective Payment System due to concerns that the policy would restrict patient access and interfere with healthcare decision-making.
July 02, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ardelyx has chosen not to apply for the inclusion of Xphozah in the CMS ESRD PPS due to concerns about patient access and healthcare decision-making.
Ardelyx's decision is based on an analysis of CMS policies that could restrict the use of Xphozah, impacting patient access and healthcare decision-making. This move is likely to be neutral in the short term as it avoids potential negative impacts from restrictive policies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100